Cited by 4,110Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.

Epidemiology of Parkinson's disease

de Lau, Lonneke ML, Breteler, Monique MB·2006·The Lancet Neurology

DOI 10.1016/s1474-4422(06)70471-9

Open this paper in CoChat — free account

Abstract

The causes of Parkinson's disease (PD), the second most common neurodegenerative disorder, are still largely unknown. Current thinking is that major gene mutations cause only a small proportion of all cases and that in most cases, non-genetic factors play a part, probably in interaction with susceptibility genes. Numerous epidemiological studies have been done to identify such non-genetic risk factors, but most were small and methodologically limited. Larger, well-designed prospective cohort studies have only recently reached a stage at which they have enough incident patients and person-years of follow-up to investigate possible risk factors and their interactions. In this article, we review what is known about the prevalence, incidence, risk factors, and prognosis of PD from epidemiological studies.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(06)70471-9

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,770
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Eeden, S. K. V. D. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,805
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I. G., Quinn, N. P., Sethi, K. D., Shults, C. W., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,011
Parkinson Disease in Twins
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 876
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G., Widner, H., Mari�, R.-M., Rémy, P., & Levivier, M. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4 · Cited by 863
The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK
MacDonald, B. K. (2000) · Brain · doi:10.1093/brain/123.4.665 · Cited by 858

Show all 119 references

Research works printed but not linked: 3

Fink, 2001, Caffeine intake and the risk of incident Parkinson's disease: the Framingham Study, Mov Disord, 16, 984
Anderson, 1999, Dietary factors in Parkinson's disease: the role of food groups and specific foods, Mov Disord, 14, 21, 10.1002/1531-8257(199901)14:1<21::AID-MDS1006>3.0.CO;2-Y · DOI
De Lau LM, Koudstaal PJ, Witteman J, Hofman A, Breteler MM. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology (in press).

Sorted by citations

Items 701–800 of 1,019

Variations in Incidence and Prevalence of Parkinson’s Disease in Taiwan: A Population-Based Nationwide Study
Liu, C., Li, C., Lee, P., & Sun, Y. (2016) · Parkinson s Disease · doi:10.1155/2016/8756359 · Cited by 65
Neurotrophic Role of the Next-Generation Probiotic Strain L. lactis MG1363-pMG36e-GLP-1 on Parkinson’s Disease via Inhibiting Ferroptosis
Yue, M., Wei, J., Chen, W., Hong, D., Chen, T., & Fang, X. (2022) · Nutrients · doi:10.3390/nu14224886 · Cited by 62
Can coffee consumption lower the risk of Alzheimer’s disease and Parkinson’s disease? A literature review
Wierzejska, R. E. (2017) · Archives of Medical Science · doi:10.5114/aoms.2016.63599 · Cited by 63
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
Fonseca, A., Reis, J., Silva, T., Matos, M. J., Bagetta, D., Ortuso, F., Alcaro, S., Uriarte, E., & Borges, F. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00918 · Cited by 62
Explorative Combined Lipid and Transcriptomic Profiling of Substantia Nigra and Putamen in Parkinson’s Disease
Xicoy, H., Brouwers, J. F. H. M., Wieringa, B., & Martens, G. J. M. (2020) · Cells · doi:10.3390/cells9091966 · Cited by 65
“PD is rare in individuals less than 50 years old, but its prevalence increases with age, reaching up to 4% in older-age groups [1].”
Background
Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson’s Disease
He, S., Wang, F., Yung, K. K. L., Zhang, S., & Qu, S. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00028 · Cited by 62
Gender distribution of patients with Parkinson’s disease treated with subthalamic deep brain stimulation; a review of the 2000–2009 literature
Hariz, G., Nakajima, T., Limousin, P. D., Foltynie, T., Zrinzo, L. U., Jahanshahi, M., & Hamberg, K. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.12.002 · Cited by 65
Lycopene Protects Against MPP+-Induced Cytotoxicity by Maintaining Mitochondrial Function in SH-SY5Y Cells
Fang, Y., He, X., & Wang, D. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1079-z · Cited by 62
Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease
de Castro, A. A., Wiemes, B. P., MATHEUS, F. C., Lapa, F. D. R., Viola, G. G., Santos, A. R. S., Tasca, C. I., & Prediger, R. D. (2013) · Brain Research · doi:10.1016/j.brainres.2013.03.029 · Cited by 62
Alcohol use disorders and risk of Parkinson’s disease: findings from a Swedish national cohort study 1972–2008
Eriksson, A.-K., Löfving, S., Callaghan, R. C., & Allebeck, P. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-190 · Cited by 60
Neuro‐ Q oL health‐related quality of life measurement system: V alidation in P arkinson's disease
Nowinski, C. J., Siderowf, A. D., Simuni, T., Wortman, C., Moy, C. S., & Cella, D. F. (2016) · Movement Disorders · doi:10.1002/mds.26546 · Cited by 63
Sigma-1 (σ1) Receptor in Memory and Neurodegenerative Diseases
Maurice, T., & Goguadze, N. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_15 · Cited by 65
Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients
Klietz, M., Greten, S., Wegner, F., & Höglinger, G. U. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00654-z · Cited by 63
Iron and other metals in the pathogenesis of Parkinson's disease: Toxic effects and possible detoxification
Bjørklund, G., Hofer, T., Nurchi, V. M., & Aaseth, J. (2019) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2019.110717 · Cited by 62
Oligomeric α-Synuclein Is Increased in Basal Tears of Parkinson’S Patients
Hamm‐Alvarez, S. F., Okamoto, C. T., Janga, S. R., Feigenbaum, D., Edman, M. C., Freire, D., Shah, M., Ghanshani, R., Mack, W. J., & Lew, M. (2019) · Biomarkers in Medicine · doi:10.2217/bmm-2019-0167 · Cited by 63
Long-Term Home-Monitoring Sensor Technology in Patients with Parkinson’s Disease—Acceptance and Adherence
Botros, A., Schütz, N., Camenzind, M., Urwyler, P., Bolliger, D., Vanbellingen, T., Kistler, R., Bohlhalter, S., Müri, R. M., Mosimann, U. P., et al. (2019) · Sensors · doi:10.3390/s19235169 · Cited by 62
“Parkinson’s disease (PD) is the second most common neurodegenerative disorder [1].”
Background
Parkinsonism and Related Disorders
Slow, E., & Lang, A. E. (2019) · DeckerMed Transitional Year Weekly Curriculum™ · doi:10.2310/tywc.1178 · Cited by 62
Impulse Control Disorders in Parkinson's Disease: Epidemiology, Pathogenesis and Therapeutic Strategies
Zhang, J., Wang, X., Feng, Y., Fekete, R., Jankovic, J. J., & Wu, Y. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.635494 · Cited by 66
Mitochondria-associated membranes: A hub for neurodegenerative diseases
Liu, J., & Yang, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112890 · Cited by 67
Depression and Cognitive Impairment in Parkinson's Disease: A Role for Inflammation and Immunomodulation?
Rocha, N. P., Reis, H. J., Berghe, P. V., & Cirillo, C. (2014) · NeuroImmunoModulation · doi:10.1159/000356531 · Cited by 61
Protective Effect of Tetrahydroxystilbene Glucoside on 6-OHDA-Induced Apoptosis in PC12 Cells through the ROS-NO Pathway
Tao, L., Li, X., Zhang, L., Jiyu, T., Li, X., Sun, X., Li, X., Jiang, L., Zhang, X., & Chen, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026055 · Cited by 61
Dietary glycemic index is inversely associated with the risk of Parkinson's disease: A case–control study in Japan
Murakami, K., Miyake, Y., Sasaki, S., Tanaka, K., Fukushima, W., Kiyohara, C., Tsuboi, Y., Yamada, T., Oeda, T., Miki, T., et al. (2009) · Nutrition · doi:10.1016/j.nut.2009.05.021 · Cited by 61
Pharmacological treatment and the prospect of pharmacogenetics in Parkinson’s disease
Kalinderi, K., Fidani, L., Katsarou, Z., & Bostantjopoulou, S. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02793.x · Cited by 61
Drug selection and timing of initiation of treatment in early Parkinson's disease
Schapira, A. H. V., & Olanow, C. W. (2009) · Annals of Neurology · doi:10.1002/ana.21460 · Cited by 61
Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson’s Disease
Graham, S. F., Rey, N. L., Ugur, Z., Yilmaz, A., Sherman, E., Maddens, M., Bahado-Singh, R. O., Becker, K., Schulz, E., Meyerdirk, L. K., et al. (2018) · Metabolites · doi:10.3390/metabo8040071 · Cited by 60
Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson’s Disease
Kelly, R. L., Joers, V. L., Tansey, M. G., McKernan, D. P., & Dowd, E. (2020) · Molecules · doi:10.3390/molecules25030453 · Cited by 58
The Effect of SPEAK OUT! and The LOUD Crowd on Dysarthria Due to Parkinson's Disease
Behrman, A., Cody, J., Elandary, S., Flom, P. L., & Chitnis, S. (2020) · American Journal of Speech-Language Pathology · doi:10.1044/2020_ajslp-19-00024 · Cited by 60
“Less commonly, younger individuals in their 30s and 40s may also develop the disease (de Lau & Breteler, 2006; Pringsheim et al., 2014).”
BackgroundInfluential
Parkinson's disease – genetic cause
Cherian, A., Divya, K. P., & Vijayaraghavan, A. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001167 · Cited by 62
Dopaminergic system and neurons: Role in multiple neurological diseases
Chen, H., Li, J., Huang, Z., Fan, X., Wang, X., Chen, X., Guo, H., Liu, H., Li, S., Yu, S., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110133 · Cited by 69
Baseline C-Reactive Protein Levels and Life Prognosis in Parkinson Disease
Sawada, H., Oeda, T., Umemura, A., Tomita, S., Kohsaka, M., Park, K., Yamamoto, K., & Sugiyama, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134118 · Cited by 60
Non-Linear EMG Parameters for Differential and Early Diagnostics of Parkinson’s Disease
Meigal, A. Y., Rissanen, S. M., Tarvainen, M. P., Airaksinen, O., Kankaanpaa, M. J., & Karjalainen, P. A. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00135 · Cited by 60
What are the issues facing Parkinson's disease patients at ten years of disease and beyond?: Data from the NPF-QII study
Hassan, A., Wu, S. S., Schmidt, P. N., Malaty, I. A., Dai, Y. F., Miyasaki, J. M., & Okun, M. S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.06.014 · Cited by 60
Risk of Obstructive Sleep Apnea in Parkinson’s Disease: A Meta-Analysis
Zeng, J., Wei, M., Li, T., Chen, W., Feng, Y., Shi, R., Song, Y., Zheng, W., & Ma, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082091 · Cited by 60
Neuroprotective effect of fucoidan from Turbinaria decurrens in MPTP intoxicated Parkinsonic mice
Meenakshi, S., Umayaparvathi, S., Saravanan, R., Manivasagam, T., & Balasubramanian, T. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.12.025 · Cited by 60
Autophagic modulation by rosuvastatin prevents rotenone-induced neurotoxicity in an in vitro model of Parkinson’s disease
Kang, S. Y., Lee, S.-B., Kim, H., Kim, H.-T., Yang, H. O., & Jang, W. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.063 · Cited by 60
Skin disorders in Parkinson’s disease: potential biomarkers and risk factors
Jørgensen, A. R., Thyssen, J. P., & Egeberg, A. (2017) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s130319 · Cited by 60
Association of statin use with Parkinson's disease: Dose–response relationship
Jeong, S., Jang, W., & Shin, D. W. (2019) · Movement Disorders · doi:10.1002/mds.27681 · Cited by 60
Building a Machine-Learning Framework to Remotely Assess Parkinson's Disease Using Smartphones
Chén, O. Y., Lipsmeier, F., Phan, H., Prince, J., Taylor, K. I., Gossens, C., Lindemann, M., & Vos, M. D. (2020) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2020.2988942 · Cited by 59
Beneficial effects of dietary restriction in aging brain
Hadem, I. K. H., Majaw, T., Kharbuli, B., & Sharma, R. (2019) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2017.10.001 · Cited by 59
Insights of Endocytosis Signaling in Health and Disease
Pathak, C., Vaidya, F. U., Waghela, B. N., Jaiswara, P. K., Gupta, V. K., Kumar, A., Rajendran, B. K., & Ranjan, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032971 · Cited by 59
Parkin, an E3 Ubiquitin Ligase, Plays an Essential Role in Mitochondrial Quality Control in Parkinson’s Disease
Wang, X., Feng, S., Wang, Z., Yuan, Y., Chen, N., & Zhang, Y. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00914-2 · Cited by 65
A Comparative In Vitro Study of the Neuroprotective Effect Induced by Cannabidiol, Cannabigerol, and Their Respective Acid Forms: Relevance of the 5-HT1A Receptors
Echeverry, C., Prunell, G., Narbondo, C., de Medina, V. S., Nadal, X., Reyes-Parada, M. I., & Scorza, C. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00277-y · Cited by 64
Neurodegenerative diseases and catechins: (−)-epigallocatechin-3-gallate is a modulator of chronic neuroinflammation and oxidative stress
Li, S., Wang, Z., Liu, G., & Chen, M. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1425839 · Cited by 64
Cross-talk between mitochondria and proteasome in Parkinson’s disease pathogenesis
Martins-Branco, D. A. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00017 · Cited by 63
Prediction potential of different handwriting tasks for diagnosis of Parkinson's
Drotár, P., Mekyska, J., Smékal, Z., Rektorová, I., Masárová, L., & Faúndez-Zanuy, M. (2013) · E-Health and Bioengineering Conference (EHB) · doi:10.1109/ehb.2013.6707378 · Cited by 59
N9 microglial cells polarized by LPS and IL4 show differential responses to secondary environmental stimuli
Liu, H., Zheng, M., Du, Y., Wang, L., Kuang, F., Qin, H., Zhang, B., & Han, H. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.06.001 · Cited by 59
Systematic Review of Traditional Chinese Medicine for Depression in Parkinson's Disease
Zhang, Y., Wang, Z., Sun, H., Li, P., Li, Y., & Chen, N. (2014) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x14500657 · Cited by 59
Occupational exposures and Parkinson's disease mortality in a prospective Dutch cohort
Brouwer, M., Koeman, T., van den Brandt, P. A., Kromhout, H., Schouten, L. J., Peters, S., Huss, A., & Vermeulen, R. C. H. (2015) · Occupational and Environmental Medicine · doi:10.1136/oemed-2014-102209 · Cited by 59
Estimating the prevalence of Parkinson's disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data
Riedel, O., Bitters, D., Amann, U., Garbe, E., & Langner, I. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4414 · Cited by 59
Genetic Variants in SNCA and the Risk of Sporadic Parkinson’s Disease and Clinical Outcomes: A Review
Campêlo, C. L. D. C., & Silva, R. H. (2017) · Parkinson s Disease · doi:10.1155/2017/4318416 · Cited by 67
Therapeutic effect of a histone demethylase inhibitor in Parkinson’s disease
Mu, M., Qian, Z., Yang, S.-X., Rong, K., Yung, W., & Ke, Y. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03105-5 · Cited by 61
The Neuroprotective Role of Polydatin: Neuropharmacological Mechanisms, Molecular Targets, Therapeutic Potentials, and Clinical Perspective
Fakhri, S., Gravandi, M. M., Abdian, S., Akkol, E. K., Farzaei, M. H., & Sobarzo‐Sánchez, E. (2021) · Molecules · doi:10.3390/molecules26195985 · Cited by 60
An optimized Nurr1 agonist provides disease-modifying effects in Parkinson’s disease models
Kim, W., Tripathi, M., Kim, C., Vardhineni, S., Cha, Y., Kandi, S. K., Feitosa, M., Kholiya, R., Sah, E., Thakur, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39970-9 · Cited by 59
Salidroside protects PC12 cells from MPP+-induced apoptosis via activation of the PI3K/Akt pathway
Zhang, L., Ding, W., Sun, H., Zhou, Q., Huang, J., Li, X., Xie, Y., & Chen, J. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.05.045 · Cited by 58
Timed motor tests can detect subtle motor dysfunction in early Parkinson's disease
Haaxma, C. A., Bloem, B. R., Overeem, S., Borm, G. F., & Horstink, M. W. I. M. (2010) · Movement Disorders · doi:10.1002/mds.23100 · Cited by 58
Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease
Fernandez, H. H., & Odin, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.560146 · Cited by 58
Factors associated with life satisfaction in Parkinson's disease
Rosqvist, K., Hagell, P., Odin, P., Ekström, H., Iwarsson, S., & Nilsson, M. H. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12695 · Cited by 58
Editor’s Highlight: Nlrp3 Is Required for Inflammatory Changes and Nigral Cell Loss Resulting From Chronic Intragastric Rotenone Exposure in Mice
Martinez, E. M., Young, A. L., Patankar, Y. R., Berwin, B. L., Wang, L., von Herrmann, K. M., Weier, J. M., & Havrda, M. C. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx117 · Cited by 59
Competing Endogenous RNA Regulations in Neurodegenerative Disorders: Current Challenges and Emerging Insights
Cai, Y., & Wan, J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00370 · Cited by 59
Predictors of Residue and Airway Invasion in Parkinson’s Disease
Curtis, J. A., Molfenter, S. M., & Troche, M. S. (2019) · Dysphagia · doi:10.1007/s00455-019-10014-z · Cited by 58
“Parkinson’s disease (PD) is a highly prevalent neurodegenerative disorder of the central nervous system, affecting 1% of all individuals over 60 years of age [1, 2].”
Prediction of Gait Freezing in Parkinsonian Patients: A Binary Classification Augmented With Time Series Prediction
Arami, A., Poulakakis-Daktylidis, A., Tai, Y., & Burdet, E. (2019) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2019.2933626 · Cited by 58
“2933626 pathologically by a progressive loss of midbrain dopaminergic neurons [1].”
Background
Pharmacological exploration of traditional plants for the treatment of neurodegenerative disorders
Wahid, M., Ali, A., Saqib, F., Aleem, A., Bibi, S., Afzal, K., Ali, A., Baig, A., Khan, S. A., & Asad, M. H. H. B. (2020) · Phytotherapy Research · doi:10.1002/ptr.6742 · Cited by 61
“It is expected that in 2030, PD will be doubled from 4.5 million to 9 million in Western Europe (de Lau & Breteler, 2006; Forsaa & Pedersen, 2008).”
BackgroundInfluential
Stem Cells on the Brain: Modeling Neurodevelopmental and Neurodegenerative Diseases Using Human Induced Pluripotent Stem Cells
Srikanth, P., & Young‐Pearse, T. L. (2014) · Journal of Neurogenetics · doi:10.3109/01677063.2014.881358 · Cited by 61
“…average ~ 40 years [Myers, 2004; Walker, 2007], ALS: average ~ 60 years [Chi ò et al., 2013; Huisman et al., 2011]; Parkinson ’ s disease: 60 years [de Lau & Breteler, 2006]; Alzheimer ’ s disease: 65 years [Thies, Bleiler, Alzheimer ’ s Association, 2013]), calling into question whether…”
In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by 18F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET
Lin, S.-C., Lin, K., Hsiao, I., Hsieh, C., Lin, W., Lu, C., Wey, S., Yen, T., Kung, M., & Weng, Y.-H. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.121897 · Cited by 57
Degeneration of mesencephalic dopaminergic neurons in klotho mouse related to vitamin D exposure
Kosakai, A., Ito, D., Nihei, Y., Yamashita, S., Okada, Y., Takahashi, K., & Suzuki, N. (2011) · Brain Research · doi:10.1016/j.brainres.2011.01.056 · Cited by 57
Accelerometry-Based Digital Gait Characteristics for Classification of Parkinson's Disease: What Counts?
Rehman, R. Z. U., Buckley, C., Micó-Amigo, M. E., Kirk, C., Dunne-Willows, M., Mazzà, C., Shi, J. Q., Alcock, L., Rochester, L., & Din, S. D. (2020) · IEEE Open Journal of Engineering in Medicine and Biology · doi:10.1109/ojemb.2020.2966295 · Cited by 57
Fatty Acid-Binding Protein 3 is Critical for α-Synuclein Uptake and MPP+-Induced Mitochondrial Dysfunction in Cultured Dopaminergic Neurons
Kawahata, I., Bousset, L., Melki, R., & Fukunaga, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215358 · Cited by 56
“Parkinson′s disease (PD) [1] is a common neurodegenerative movement disorder which affects approximately 1% of people aged > 60 years [2,3].”
Background
Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention – A Comparison with Parkinson’s Disease
DeVaughn, S., Müller‐Oehring, E. M., Markey, B. M., Bronte-Stewart, H. M., & Schulte, T. (2015) · Neuropsychology Review · doi:10.1007/s11065-015-9305-x · Cited by 56
Considerations for general anaesthesia in Parkinson’s disease
Roberts, D. P., & Lewis, S. J. G. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.10.062 · Cited by 56
Proactive and Integrated Management and Empowerment in Parkinson’s Disease: Designing a New Model of Care
Tenison, E., Smink, A. J., Redwood, S., Darweesh, S. K. L., Cottle, H., van Halteren, A. D., van den Haak, P., Hamlin, R., Ypinga, J. H. L., Bloem, B. R., et al. (2020) · Parkinson s Disease · doi:10.1155/2020/8673087 · Cited by 56
“3% of the population in industrialized countries have PD, rising to 1% in those aged over 60 years [2].”
A review on preventive role of ketogenic diet (KD) in CNS disorders from the gut microbiota perspective
Rawat, K., Singh, N., Kumari, P., & Saha, L. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0078 · Cited by 61
Microglia Specific Drug Targeting Using Natural Products for the Regulation of Redox Imbalance in Neurodegeneration
Maurya, S. K., Bhattacharya, N., Mishra, S., Bhattacharya, A., Banerjee, P., Senapati, S., & Mishra, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.654489 · Cited by 59
Diffusion tensor imaging along the perivascular space: the bias from crossing fibres
Georgiopoulos, C., Werlin, A., Lasič, S., Hall, S., van Westen, D., Spotorno, N., Hansson, O., & Nilsson, M. (2024) · Brain Communications · doi:10.1093/braincomms/fcae421 · Cited by 55
Parkinson's disease: A risk factor for osteoporosis
Malochet‐Guinamand, S., Durif, F., & Thomas, T. (2015) · Joint Bone Spine · doi:10.1016/j.jbspin.2015.03.009 · Cited by 55
Current strategies in the treatment of Parkinson’s disease and a personalized approach to management
Diaz, N. L., & Waters, C. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.117 · Cited by 56
Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic Studies
Politi, C., Ciccacci, C., Novelli, G., & Borgiani, P. (2018) · NeuroMolecular Medicine · doi:10.1007/s12017-017-8473-7 · Cited by 56
Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics
Bardai, F. H., Ordonez, D. G., Bailey, R. M., Hamm, M. J., Lewis, J. M., & Feany, M. Β. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2006265 · Cited by 55
Mitochondrial Dysfunction Combined with High Calcium Load Leads to Impaired Antioxidant Defense Underlying the Selective Loss of Nigral Dopaminergic Neurons
Ricke, K. M., Paß, T., Kimoloi, S., Fährmann, K., Jüngst, C., Schauss, A. C., Baris, O. R., Croon, M., Trifunović, A., Faelker, T. M. E., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1345-19.2019 · Cited by 57
Dopamine, Alpha-Synuclein, and Mitochondrial Dysfunctions in Parkinsonian Eyes
Indrieri, A., Pizzarelli, R., Franco, B., & Leonibus, E. D. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.567129 · Cited by 57
Dietary Antioxidants and the Risk of Parkinson Disease
Hantikainen, E. M., Lagerros, Y. T., Ye, W., Serafini, M., Adami, H., Bellocco, R., & Bonn, S. E. (2021) · Neurology · doi:10.1212/wnl.0000000000011373 · Cited by 58
Edaravone leads to proteome changes indicative of neuronal cell protection in response to oxidative stress
Jami, M., Salehi-Najafabadi, Z., Ahmadinejad, F., Hoedt, E., Chaleshtori, M. H., Ghatrehsamani, M., Neubert, T. A., Larsen, J. P., & Møller, S. G. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.07.024 · Cited by 56
“…which affects approximately 1% of individuals above 60 years of age, and is characterized by cumulative ciences, St John's University, 8 990 1894. ami), Zahra.salehi@live.com (F. Ahmadinejad), Esthelle. oedt), mchalesh@yahoo.com (T.A. Neubert), jpl@sus.no neuronal loss (De Lau and Breteler, 2006).”
The coenzyme Q10 status of the brain regions of Parkinson’s disease patients
Hargreaves, I. P., Lane, A., & Abou‐Sleiman, P. M. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.09.069 · Cited by 56
Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson’s Disease
Leggio, L., Paternò, G., Vivarelli, S., Falzone, G. G., Giachino, C., Marchetti, B., & Iraci, N. (2021) · Aging and disease · doi:10.14336/ad.2021.0527 · Cited by 55
Therapy With Mesenchymal Stem Cells in Parkinson Disease
Filho, D. M., Ribeiro, P. D. C., de Oliveira, L. F., de Paula, D. R. M., Capuano, V., Farnesi-de-Assunção, T. S., & da Silva, V. J. D. (2018) · The Neurologist · doi:10.1097/nrl.0000000000000188 · Cited by 55
Changes in Drp1 Function and Mitochondrial Morphology Are Associated with the α-Synuclein Pathology in a Transgenic Mouse Model of Parkinson’s Disease
Portz, P., & Lee, M. K. (2021) · Cells · doi:10.3390/cells10040885 · Cited by 55
Risk factors for the development of degenerative cervical myelopathy: a review of the literature
Baucher, G., Taskovic, J., Troude, L., Molliqaj, G., Nouri, A., & Tessitore, E. (2021) · Neurosurgical Review · doi:10.1007/s10143-021-01698-9 · Cited by 59
Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson’s Disease: Preclinical and Clinical Studies
Hong, C., Chan, L., Chen, K., Lee, H., Huang, L., Yang, Y. S. H., Liu, Y., & Hu, C. (2022) · Cells · doi:10.3390/cells11213468 · Cited by 59
The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews
Dagan, E., Schlesinger, I., Ayoub, M., Mory, A., Nassar, M., Kurolap, A., Peretz-Aharon, J., & Gershoni‐Baruch, R. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.06.016 · Cited by 58
“Parkinson is a multifactorial disease that affects 1% of the population over 65 years of age [1].”
Background
EMG signal morphology and kinematic parameters in essential tremor and Parkinson’s disease patients
Ruonala, V., Meigal, A. Y., Rissanen, S. M., Airaksinen, O., Kankaanpaa, M. J., & Karjalainen, P. A. (2014) · Journal of Electromyography and Kinesiology · doi:10.1016/j.jelekin.2013.12.007 · Cited by 55
The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson’s disease
Shearer, J., Green, C., Counsell, C. E., & Zajicek, J. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6202-y · Cited by 55
Contribution of Yeast Models to Neurodegeneration Research
Pereira, C., Bessa, C., Soares, J., Leão, M., & Saraiva, L. (2012) · BioMed Research International · doi:10.1155/2012/941232 · Cited by 58
Neuronal adhesion, proliferation and differentiation of embryonic stem cells on hybrid scaffolds made of xanthan and magnetite nanoparticles
Glaser, T., Bueno, V. B., Cornejo, D. R., Petri, D. F. S., & Ulrich, H. (2015) · Biomedical Materials · doi:10.1088/1748-6041/10/4/045002 · Cited by 55
Curcumin improves neurofunctions of 6-OHDA-induced parkinsonian rats
Song, S., Nie, Q., Li, Z., & Du, G. (2015) · Pathology - Research and Practice · doi:10.1016/j.prp.2015.11.012 · Cited by 55
Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson’s Disease
Zhao, J., Yu, S., Zheng, Y., Yang, H., & Zhang, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9743-3 · Cited by 58
The small heat shock proteins αB-crystallin (HSPB5) and Hsp27 (HSPB1) inhibit the intracellular aggregation of α-synuclein
Cox, D., & Ecroyd, H. W. (2017) · Cell Stress and Chaperones · doi:10.1007/s12192-017-0785-x · Cited by 55
“…21 Parkinson’s disease (PD) is the second most prevalent form of age-related neurodegenerative 22 disorder, with its world-wide incidence projected to reach at least 8.7 million individuals over 50 23 years of age by 2030 (de Lau and Breteler 2006, Dorsey et al. 2007, Massano and Bhatia 2012).”
Influential
Assessment of residential environmental exposure to pesticides from agricultural fields in the Netherlands
Brouwer, M., Kromhout, H., Vermeulen, R. C. H., Duyzer, J. H., Kramer, H., Hazeu, G. W., de Snoo, G., & Huss, A. (2017) · Journal of Exposure Science & Environmental Epidemiology · doi:10.1038/jes.2017.3 · Cited by 55
Exploring the microbiome in health and disease
Scotti, E., Boué, S., Sasso, G. L., Zanetti, F., Belcastro, V., Poussin, C., Sierro, N., Battey, J. N. D., Gimalac, A., Ivanov, N. V., et al. (2017) · Toxicology Research and Application · doi:10.1177/2397847317741884 · Cited by 56
Plasma extracellular vesicles tau and β‐amyloid as biomarkers of cognitive dysfunction of Parkinson's disease
Chung, C., Chan, L., Chen, J., Bamodu, O. A., Chiu, H., & Hong, C. (2021) · The FASEB Journal · doi:10.1096/fj.202100787r · Cited by 55
Tissue-Specific Landscape of Metabolic Dysregulation during Ageing
Zhang, F., Kerbl-Knapp, J., Akhmetshina, A., Korbelius, M., Kuentzel, K. B., Vujić, N., Hörl, G., Paar, M., Kratky, D., Steyrer, E., et al. (2021) · Biomolecules · doi:10.3390/biom11020235 · Cited by 52
Dopaminergic Modulation of Arm Swing During Gait Among Parkinson's Disease Patients
Sterling, N. W., Cusumano, J. P., Shaham, N., Piazza, S. J., Liu, G., Kong, L., Du, G., Lewis, M. M., & Huang, X. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-140447 · Cited by 54

Authors: de Lau, L. M., & Breteler, M. M.
Affiliations: Erasmus MC (NL)
Corresponding author: Breteler, Monique MB
ORCID: Breteler, Monique MB
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2006-06
Volume: 5
Issue: 6
Pages: 525-535
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(06)70471-9
OpenAlex: W2134886133
Cited by: 4,110
References: 119
Citations by year: 2026: 108 · 2025: 172 · 2024: 229 · 2023: 230 · 2022: 307 · 2021: 315 · 2020: 337 · 2019: 290 · 2018: 301 · 2017: 284 · 2016: 259 · 2015: 288 · 2014: 232 · 2013: 200 · 2012: 159
FWCI: 7.02
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Parkinson's disease, prevalence, incidence, risk factors, prognosis, genetic susceptibility, gene-environment interaction, neurodegeneration, prospective cohort
MeSH terms: Age Factors, Humans, Parkinson Disease, Prognosis, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks